Squamous Cell Carcinoma — Trials

Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 976
Recruiting: 519
Ph III recruiting: 60
Growth YoY: +44.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (402)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01810913	Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	suspended	Phase 2 / Phase 3	613	National Cancer Institute (NCI)NIH	3	Sep 1, 2026	clinicaltrials
NCT06568172	Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer	suspended	Phase 3	420	National Cancer Institute (NCI)NIH	3	Sep 1, 2026